Clinical Trial Update: Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing once-daily Mirapex ER to twice-daily dosing in Parkinson's disease; status is unknown in the document.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Mirapex ER (pramipexole)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Parkinson's Disease | Phase 4 | Status: UNKNOWN